Despite recognition of pathogenic antibodies against the water channel aquaporin 4 (AQP4) in the majority of patients with NMO/NMO-SD[1–3], diagnosis of especially seronegative cases can be challenging and underlines the need for additional biomarkers[4, 5]. This evidence concerns the gene AQP4 and Salla disease.